Science & Innovation Theaters provide a structured focus for participants to learn about specific products, therapeutic areas, and/or disease states in presentations given by company-designated presenters.
All theaters will take place in the Expo.
Materials presented in theaters may be promotional and concentrate on a specific product, service, or therapeutic area. Therefore, these presentations are considered promotional and do not offer continuing education credit.
Thursday, March 23 | 11:15–11:45am
A Review of Rett Syndrome, a Rare Neurodevelopment Disorder and Management Considerations
Description: Join Acadia Pharmaceuticals, a leader in neuroscience, to learn about Rett syndrome, a rare progressive neurodevelopmental genetic disorder with profound functional impairments. Rett symptoms include loss of purposeful hand use, impaired ambulation, stereotypical hand movements and loss of language and intellectual abilities. Therefore, patients often require around-the-clock assistance with all aspects of daily living. Current management is primarily supportively, leaving the core symptoms unmanaged.This Science & Innovation Theater will provide information on the complexity of Rett syndrome and management considerations for this devastating disease.
- Mary Kay Koenig, MD
The University of Texas Medical School at Houston, Division of Child & Adolescent Neurology
Sponsored by Acadia Pharmaceuticals
Description: This Science & Innovation Theater will provide information on the relevant clinical data for zuranolone, an investigational product targeting patients with major depressive disorder and postpartum depression. Zuranolone is an investigational compound that has not been FDA-approved for use; therefore, its safety and efficacy have not been established.
- Dr. Gary Owens, MD
Medical Director to Patient Access Network Foundation
Member of the Editorial Board of American Health and Drug Benefits, Value Based Care in Neurology, Journal of Managed Care Medicine, Journal of Managed Care + Specialty Pharmacy, First Report Managed Care, Journal of Clinical Pathways and Clinical Therapeutics.
Sponsored by Sage Therapeutics & Biogen
Thursday, March 23 | Noon–12:30pm
FILSPARI: A Newly Approved Treatment for Adults with Primary Immunoglobulin A Nephropathy (IgAN) at Risk of Rapid Progression
Description: Immunoglobulin A nephropathy (IgAN) is a rare glomerulonephritis generally diagnosed in younger adults, which often progresses to kidney failure before a confirmed diagnosis. This Science & Innovation Theatre will provide information on IgAN disease progression, the role of proteinuria reduction in lowering the relative risk of kidney failure, and the unmet need for patients at high risk of disease progression. We will then introduce relevant clinical data for FILSPARI, a newly approved treatment for adults with primary IgAN at risk of rapid disease progression. FILSPARI is approved under accelerated approval based on a relative change from baseline in UPCR at week 36.
- Dr. Saravanan Balamuthusamy, MD, FASN, FASDIN
Professor of Medicine & Nephrology, TCU
OptMyCare, Co-Founder & Chairman
Sponsored by Travere Therapeutics
Description: Join us for an informative case-based discussion on the use of BRUKINSA for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The discussion will include the results from the latest BRUKINSA clinical trials as well as information on cost of therapy, dosing & administration, and patient support.
- Kirollos Hanna, PharmD, BCPS, BCOP
Director of Pharmacy, Minnesota Oncology, St. Paul, MN
Sponsored by BeiGene
Thursday, March 23: 12:45–1:15pm
Molecular Diagnostics: Can They Really Reduce Oncology Costs, Waste, and Harm?
Description: Cancer treatment and outcomes are increasingly dependent on both a histologic and a molecular diagnosis. This session will focus on:
- The basics of molecular diagnostic testing in cancer, explaining the differences in single gene, multi-gene panels, and comprehensive genomic profiling (CGP).
- The critical role molecular diagnostic testing plays in getting patients on the appropriate therapy upfront, avoiding waste from therapies that patients are unlikely to respond to, and avoiding the harms associated with suboptimal treatments.
- The impact of CGP-guided treatments on the total cost of care, including drugs spend.
- The evidence supporting the clinical utility and economic utility of molecular diagnostic testing.
- The role that health plans can play in promoting optimal management and evidence-based care through comprehensive genomic testing.
Cancer treatment and outcomes are increasingly dependent on both a histologic and a molecular diagnosis. This session will focus on the basics of molecular diagnostic testing in cancer, explaining the differences in single-gene, multi-gene panels, and comprehensive genomic profiling (CGP). Molecular diagnostic testing plays a critical role in getting patients on the appropriate therapy upfront, avoiding waste from therapies that patients are unlikely to respond to, and avoiding the harms associated with suboptimal treatments. We will also explore the impact of CGP-guided clinical trials on the total cost of care, including drugs spend. Finally, we will examine the evidence supporting the clinical utility and economic utility of molecular diagnostic testing and the role that health plans can play in promoting optimal management and evidence-based care through comprehensive genomic testing.
- Jen Oh, PharmD
Illumina Senior Manager, Global Strategy & Operations
- John Fox, MD MHA
Illumina Senior Medical Director for the Americas
Sponsored by Illumina
Thursday, March 23 | 1:30–2pm
Omnipod® — A Portfolio of Tubeless, On-Body Insulin Delivery Solutions for People with Diabetes
Description: At Insulet, our mission is to improve the lives of people with diabetes and enable our customers to enjoy simplicity, freedom, and healthier lives through innovative technology. Our Omnipod® brand provides continuous insulin delivery through a wearable, tubeless, waterproof* insulin delivery solution called a Pod. Our portfolio consists of the Omnipod® 5 Automated Insulin Delivery System, the Omnipod DASH® Insulin Management System and Insulet® has submitted to the FDA an Omnipod Basal-Only Pod (Pending 510(k), not available for sale within the United States). This presentation will provide an overview of our portfolio, including a comparison of indications, patient types, and product features to help formulary decision-makers understand the role and value of each solution within the treatment journey for people with diabetes.
* The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Controller/Personal Diabetes Manager is not waterproof.
- Joyce Freehling RD, LDN, CDCES
National Clinical Science Liaison, Insulet Corporation
Sponsored by Insulet
The Value of HEMGENIX for Hemophilia B
Description: Join CSL Behring, a manufacturer with decades of experience creating treatments for bleeding disorders, to discuss the first and only FDA-approved gene therapy for hemophilia B. This rare, X-linked, hereditary disorder is characterized by bleeding, pain, and long-term complications. Current treatment includes lifelong prophylactic infusions of factor IX to temporarily replace or supplement low levels of the blood-clotting factor. Prophylactic treatment is associated with a significant economic burden and despite treatment, clinical burdens still exist. Gene therapy presents potentially historic economic and clinical implications for the treatment of this rare disease.
- Christine Donahue, MSN, NP,
CSL Behring Medical Outcomes Specialist, Medical Affairs
- Robert Rouse, MS,
CSL Behring Head of Market Access
Sponsored by CSL Behring
Science & Innovation Theaters with a PIE logo include preapproval information exchange information. In accordance with federal laws and regulations, attendance at these sessions is restricted to payors, formulary committees, or other similar entity representatives with knowledge and expertise in health care economic analysis, carrying out responsibilities for the selection of drugs for coverage or reimbursement. Look for additional details on the PIE information page.
Additional Science & Innovation Theater sponsorship opportunities may be available. Contact Rebecca Mercado, senior manager of exhibits and sponsorships, at email@example.com for more details.